Caprock Group LLC Makes New $1.48 Million Investment in Illumina, Inc. $ILMN

Caprock Group LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 14,794 shares of the life sciences company’s stock, valued at approximately $1,479,000.

Several other hedge funds have also recently bought and sold shares of ILMN. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after purchasing an additional 99 shares in the last quarter. Versant Capital Management Inc increased its holdings in Illumina by 8.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after purchasing an additional 111 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Archer Investment Corp increased its position in shares of Illumina by 12.9% during the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after purchasing an additional 123 shares during the last quarter. Finally, Callan Family Office LLC increased its holdings in Illumina by 4.4% during the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after buying an additional 124 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

Illumina stock opened at $116.81 on Friday. The firm’s fifty day moving average price is $137.29 and its 200-day moving average price is $116.57. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a market cap of $17.85 billion, a P/E ratio of 21.43, a price-to-earnings-growth ratio of 2.23 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the business posted $0.95 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of research reports. Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Stifel Nicolaus raised their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. JPMorgan Chase & Co. cut their target price on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Guggenheim increased their price target on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, UBS Group restated a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and an average price target of $129.17.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.